U.S.A.s interesting latest

We will end ‘catch and release’  On Friday, President Donald J. Trump signed a Presidential Memorandum that takes important steps to end “catch and release,” a dangerous practice whereby those who have violated our Nation’s immigration laws are released into the United States shortly after their apprehension. The Memo’s opening lines lay out the challenge facing our country: Human smuggling operations, gang member entry, and other criminal activity spilling across the U.S. border threaten our security and safety. The backlog of immigration cases is alarmingly large and has hindered the quick resolution of outstanding cases. Shortages in border-security and immigration enforcement personnel have reached critical levels. In response, President Trump has asked his Secretary of Homeland Security to produce a report within 45 days that details how the Administration is acting swiftly to end these “catch and release” practices. He also renews his call for Congressional Democrats to join Republicans to pass comprehensive immigration reform. Read the President’s full Memo on ending “catch and release.” The fight on opioid abuse takes center stage  President Trump traveled to New Hampshire three weeks ago to lay out his plan for how America will win the war on opioid and drug abuse. This week marks another important step toward that goal. Today, opioids will take center stage at the twelfth meeting of President Trump’s Cabinet. He will receive updates from Counselor to the President Kellyanne Conway, who is helping spearhead the White House’s initiative, along with Health and Human Services Secretary Alex Azar and Attorney General Jeff Sessions. Later this week, a temporary memorial to victims of opioid abuse will be on exhibition just outside the White House on the Ellipse at President’s Park. It will remain open through Wednesday, April 18. Learn more about President Trump’s initiative to stop the opioid epidemic. One important group of Americans is doing very well The Bureau of Labor Statistics released its monthly jobs report on Friday, which showed that nonfarm payroll employment rose by more than 100,000 in March. Following exceptional job growth in January and February, the U.S. economy is adding more than 200,000 jobs per month on average so far in 2018. Job gains during the Trump Administration have lowered the unemployment rate for all major demographic groups in the United States. One important and often-overlooked group in particular has felt the benefits of accelerated economic growth: Americans with disabilities. Americans with one or more disability have typically experienced higher jobless rates than the average citizen. The unemployment rate for men with a disability has dropped by 3 percentage points since President Trump took office, and the unemployment rate for women with a disability has fallen by 2.6 percentage points. These numbers even outpace the decline in joblessness across other groups. Read more: Job growth in the first quarter of 2018 remains strong PHOTO OF THE DAY The White House | April 5, 2018 (Official White House Photo by Joyce N. Boghosian) POTUS TODAY This morning, President Trump will host a meeting with his Cabinet. This afternoon, Vice President Mike Pence will participate in a swearing-in ceremony for Mississippi’s Senator-designate Cindy Hyde-Smith, and a swearing-in ceremony for Carla Sands as the U.S. Ambassador to the Kingdom of Denmark. Later, the President and Vice President will receive a briefing and have dinner with Senior Military Leadership. ======================================= Stewart’s Shops Issues Allergy Alert on Pint Chocolate Peanut Butter Cup Ice Cream Stewart’s Shops Corp. is recalling units of Stewart’s pint Chocolate Peanut Butter Cup ice cream because they may have been packaged incorrectly with a “Chocolate” lid.  People who have an allergy to peanuts run the risk of serious or life-threatening allergic reaction if they consume this product. The affected product was distributed in upstate New York and Southern Vermont. The Stewart’s pint Chocolate Peanut Butter Cup ice cream is packaged in a 16 oz. cardboard container, UPC 0 82086 44468 8. Affected units have a Sell By code date of 08/23/18 which can be found on the bottom of the package.  All other expiration code dates of Stewart’s pint Chocolate Peanut Butter Cup ice cream are not affected by this recall. No illnesses have been reported to date in connection with this problem. For consumers who are not allergic to peanuts, there is no safety issue with this product. The recall was initiated after it was discovered that a Stewart’s pint Chocolate ice cream lid had been found on a Stewart’s pint Chocolate Peanut Butter Cup ice cream container. Essure Permanent Birth Control System by Bayer Healthcare: Announcement - FDA Restricts the Sale and Distribution AUDIENCE: OBGYN, Patient, Risk Manager ISSUE: The FDA is aware that some women have received the Essure device without being adequately informed of Essure’s risks. In order for this device to meet reasonable assurance of safety and effectiveness, all women considering Essure should receive this important information. On April 9, 2018, the FDA restricted sales of the Essure device to only doctors and healthcare facilities who use the FDA-approved “Patient-Doctor Discussion Checklist – Acceptance of Risk and Informed Decision Acknowledgement”. Sale and distribution of Essure is limited to healthcare providers who agree to review this checklist with patients, and give them the opportunity to sign it, before Essure implantation. The FDA has approved this new safety measure to ensure that the device meets standards for a reasonable assurance of safety and effectiveness. The FDA also approved Bayer's new labeling that includes: The following statement: “The sale and distribution of this device are restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Bayer.” Bayer’s Patient-Doctor Discussion Checklist – Acceptance of Risk and Informed Decision Acknowledgement, which is part of the patient information booklet, and has key items about the device, its use, and safety and effectiveness outcomes, which the patient should be aware of as they consider permanent birth control options. BACKGROUND: The FDA wants to ensure that each and every woman who receives Essure has been informed of the risks and benefits before getting the device implanted. The FDA has taken steps, including labeling changes in 2016 adding a boxed warning and patient decision checklist, to better inform health care providers and patients about the risks. RECOMMENDATION: Health care providers should thoroughly discuss available sterilization and birth control methods with their patients, including their benefits and risks. The FDA-approved Decision Checklist based on the Final Guidance should be used to facilitate these discussions and ensure patients understand the benefits and risks. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: Complete and submit the report Online: www.fda.gov/MedWatch/report Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Read the MedWatch Safety Alert, including a link to the FDA announcement, at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm604126.htm Club 13 Recalls Kratom Maeng Da Red Powder and Capsules Because of Possible Health Risk Club 13 of St. Augustine, FL is recalling 15-gram, 30-gram, 90-gram, 150-gram, and 454-gram pouches, and all bulk orders of "Maeng Da Red" kratom powder; and 5-count, 25-count, 50-count, 100-count, 120-count capsule, and all bulk capsule orders of “Maeng Da Red” kratom bottles; and 5-count, 20-count, 25-count, 40-count, 50-count capsule “Maeng Da Red XS” kratom bottles because they have the potential to be contaminated with Salmonella , an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. Bob’s Red Mill Natural Foods, Inc. Voluntarily Recalls Organic Amaranth Flour (22 Oz.) Because of Possible Health Risk Bob’s Red Mill Natural Foods is voluntarily recalling 2,099 cases of Organic Amaranth Flour (22 oz.), after recent testing revealed the presence of Salmonella in a single LOT of Organic Amaranth Flour (22 oz.) with a Sell By date of Nov. 26, 2015. Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and produce more severe illnesses. The recalled Organic Amaranth Flour (22 oz.) was distributed through retailers and distributors nationwide. This product and LOT was distributed in CA, FL, MI, ND, N, NY, OH, OR, TX, and WA starting June 11, 2014 and ended shipping on August 7, 2014. FTC Staff Comment Supports Proposal to Enhance Access to Dental Care in New York Federal Trade Commission staff submitted a comment to the New York State Education Department (NYSED) in support of a proposed regulatory change that would reduce the burdens on experienced, Canadian dentists wishing to practice dentistry within New York State. This change would allow established, Canadian dentists to use the same process that experienced U.S. dentists from other U.S. states use to become licensed in New York State. Responding to the NYSED’s request for public comments, staff of the FTC’s Office of Policy Planning and its Bureaus of Competition and Economics stated that the proposed amendment would significantly reduce the current barriers to licensure for Canadian dentists whose education and training are comparable to that of U.S. dentists. By reducing the barriers to licensure of Canadian dentists, the proposed amendment will increase the pool of dentists qualified for licensure in New York. Canadian dentists who obtain authorization to practice in New York may improve access to dental services in underserved areas of the state, such as the North Country region. This change could also improve dental schools’ ability to recruit Canadian dentists to faculty positions, which could increase access to care in nearby communities. By increasing the available supply of qualified dentists, the proposed amendment likely would increase competition among dentists practicing in New York. The benefits of additional competition could include an increased range of choices available to consumers, improved dental outcomes, and reduced dental costs for consumers. The Commission vote to issue the staff comment was 2-0. It was sent to the New York State Education Department on April 6, 2018. (FTC File No. V180007; the staff contact is Karen A. Goldman, Office of Policy Planning, 202-326-2574). Get Your Toughest Financial Questions Answered Whether you're doing research on applying for a credit card or learning how to tackle your student loans, managing your finances is an important skill to have. When your financial questions come up, Ask CFPB from the Consumer Financial Protection Bureau is a great resource to get unbiased information and make more informed decisions about your money.